For Q3 FY2023 (ended September 30, 2022), Lexeo Therapeutics reported revenue of $531,000. Net loss was $20.2 million, compared to a loss of $14.6 million in the prior year period. Operating loss was $22.3 million, and diluted EPS was -$0.25.
•Revenue of $531,000 in Q3 FY2023.
•Net loss of $20.2 million, up 38.2% year-over-year.
•Operating loss of $22.3 million, up 33.9% year-over-year.
•Diluted EPS of -$0.25, compared to -$0.14 in the prior year.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy.
Its portfolio also includes LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM, and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death
Including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy.
Additionally, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program.
Its portfolio also includes a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology, and third license agreement which obtained certain rights for FA cardiomyopathy
Including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. Founded in 2017, the company is headquartered in New York, New York.
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company based in the United States. It focuses on developing gene therapies for hereditary and acquired diseases with high unmet need. Its pipeline includes LX2006, an AAVrh10-based gene therapy candidate in phase 1/2 clinical trial for Friedreich ataxia cardiomyopathy. It also has LX2020, in phase 1/2 for PKP2-ACM, and preclinical candidates LX2021 for arrhythmogenic cardiomyopathy and dilated cardiomyopathy, LX2022 for hypertrophic cardiomyopathy, and LX1001, LX1020, and LX1021 for APOE4-associated Alzheimer's disease. The company collaborates with Cornell University on certain programs.
On which exchange is Lexeo Therapeutics (LXEO) listed and in what currency?
Lexeo Therapeutics is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol LXEO. Its financials are reported in US Dollars (USD), reflecting its operations based in the United States.
What sector and industry does Lexeo Therapeutics (LXEO) operate in?
Lexeo Therapeutics operates in the Healthcare sector and specifically within the Biotechnology industry. As a clinical stage genetic medicine company, it focuses on developing gene therapies for serious hereditary and acquired diseases, particularly those affecting the heart and brain.
Where is Lexeo Therapeutics (LXEO) headquartered and what markets does it serve?
Lexeo Therapeutics is headquartered in the United States and primarily serves the US market. Its clinical trials and research activities are conducted in the US, and it collaborates with institutions like Cornell University to advance its gene therapy programs.
What are the key product candidates in Lexeo Therapeutics' (LXEO) pipeline?
Lexeo Therapeutics has a pipeline of gene therapy candidates targeting cardiac and neurological diseases. Key candidates include LX2006 for Friedreich ataxia cardiomyopathy (phase 1/2), LX2020 for PKP2-ACM (phase 1/2), and preclinical programs LX2021 for arrhythmogenic and dilated cardiomyopathies, LX2022 for hypertrophic cardiomyopathy, and LX1001, LX1020, and LX1021 for APOE4-associated Alzheimer's disease. The company also has a license agreement with Cornell University for the LX1001 trial and preclinical research collaboration.